Evidence map›Paper›PMID 35767123›Full record

Observational studyAdvances in therapy2022

Real-World Status of Medical Care and Treatment of Chronic Obstructive Pulmonary Disease by Respiratory Specialists in Japan.

Shu Hashimoto, Ryoko Sorimachi, Naoyuki Makita, Naoki Tashiro, Satoko Sugaya, Yoshifumi Arita, Masakazu Ichinose

Erratum issued Registry-linked trialOpen access · hybridAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Advances in therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03577795 (A Prospective Cohort Study of Asthma and COPD Overlap in Japanese COPD Patients Using the Diagnostic Criteria of The Japanese Respiratory Society), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03577795 completednot on this map

A Prospective Cohort Study of Asthma and COPD Overlap in Japanese COPD Patients Using the Diagnostic Criteria of The Japanese Respiratory Society

Typeobservational_patient_registrySponsorAstraZenecaRan2018 to 2021Enrolled710ConditionsPulmonary Disease, Chronic Obstructive
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Shu HashimotoNihon University, Itabashi-ku, Tokyo, Japan. hashimoto.shu@nihon-u.ac.jp.ORCID 0000-0002-7173-8796
Ryoko SorimachiMedical Department, AstraZeneca K.K., Kita-ku, Osaka, Japan.
Naoyuki MakitaMedical Department, AstraZeneca K.K., Kita-ku, Osaka, Japan.
Naoki TashiroMedical Department, AstraZeneca K.K., Kita-ku, Osaka, Japan.
Satoko SugayaMedical Department, AstraZeneca K.K., Kita-ku, Osaka, Japan.
Yoshifumi AritaMedical Department, AstraZeneca K.K., Kita-ku, Osaka, Japan.
Masakazu IchinoseAcademic Center of Osaki Citizen Hospital, 3-8-1 Honami, Furukawa, Osaki, Miyagi, 989-6183, Japan. ichinose@h-osaki.jp.
AstraZeneca (Japan) · JPNihon University · JPOsaki Citizen Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe ACO Registry Study was a multicenter, prospective, observational cohort study aiming to clarify the situation of asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) within the COPD population using the Japanese Respiratory Society (JRS) criteria. We reported the proportion of patients who met the ACO criteria among the COPD population at study registration.

methodsUsing data collected at registration, we investigated the implementation of each diagnostic examination/test required for ACO diagnosis in the full analysis set. Among patients with data necessary for ACO diagnosis, ACO/non-ACO patients with/without asthma diagnosed by a physician and proportions of inhaled corticosteroid (ICS) treatments for COPD were calculated.

resultsOf 708 patients analyzed, 396 (55.9%) had the data necessary for ACO diagnosis, and 312 (44.1%) did not. The proportions of patients who underwent laboratory and respiratory function tests (peripheral blood eosinophil count [79.8%], fractional exhaled nitric oxide [63.7%], airway reversibility [46.8%], and total immunoglobulin [Ig] E/specific IgE [33.3%]) were lower than those who underwent subjective examinations (perennial allergic rhinitis [100%], asthma before age 40 years [97.2%], and variable/paroxysmal respiratory symptoms [94.5%]). Among patients with the data necessary for ACO diagnosis and without asthma complications according to the physician's diagnosis, 15.1% (33/219) met the ACO criteria. Of patients who met the ACO criteria, 74.3% (75/101) received ICS, and 25.7% (26/101) did not. By comparison, among patients who did not meet the ACO criteria, 35.6% (105/295) were receiving ICS, and 64.4% (190/295) were not.

conclusionsThe proportion of objective laboratory and physiological tests was lower than expected, despite study sites having the clinical resources for objective tests. Most ACO patients were being treated with ICS as recommended in the JRS treatment guidelines. Attempts should be made to further increase the proper use of ICS among these patients in Japan.

trial registrationClinicalTrials.gov, NCT03577795.

Indexed as

AsthmaPulmonary Disease, Chronic ObstructiveAdrenal Cortex HormonesAdultHumansImmunoglobulin EJapanNitric OxideProspective StudiesAdrenal Cortex HormonesImmunoglobulin ENitric OxideAsthma–COPD overlapBlood eosinophil countChronic obstructive pulmonary diseaseFractional exhaled nitric oxideImmunoglobulin EInhaled corticosteroid

Identifiers

PMID35767123
PMCPMC9464737
OpenAlexW4283697791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.